{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T15:30:25Z","timestamp":1783006225012,"version":"3.54.5"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s13346-025-01911-y","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T15:34:14Z","timestamp":1757000054000},"page":"563-578","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Targeted delivery of IFN-\u03b1-anti-GPC3 fusion protein via mRNA-LNP platform elicits potent anti-tumor immunity in hepatocellular carcinoma"],"prefix":"10.1007","volume":"16","author":[{"given":"Yajie","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruyue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyan","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuehang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"1911_CR1","doi-asserted-by":"crossref","unstructured":"T\u00fcmen D et al. Pathogenesis and current treatment strategies of hepatocellular carcinoma. Biomedicines, 2022. 10(12).","DOI":"10.3390\/biomedicines10123202"},{"issue":"1","key":"1911_CR2","doi-asserted-by":"publisher","first-page":"101","DOI":"10.4254\/wjh.v7.i1.101","volume":"7","author":"MA Kalogeridi","year":"2015","unstructured":"Kalogeridi MA, et al. Role of radiotherapy in the management of hepatocellular carcinoma: A systematic review. World J Hepatol. 2015;7(1):101\u201312.","journal-title":"World J Hepatol"},{"issue":"4","key":"1911_CR3","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1159\/000449336","volume":"5","author":"MC Ho","year":"2016","unstructured":"Ho MC, et al. Surgery for intermediate and advanced hepatocellular carcinoma: A consensus report from the 5th Asia-Pacific primary liver Cancer expert meeting (APPLE 2014). Liver Cancer. 2016;5(4):245\u201356.","journal-title":"Liver Cancer"},{"key":"1911_CR4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2147\/JHC.S106529","volume":"4","author":"D Galun","year":"2017","unstructured":"Galun D, et al. Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies. J Hepatocell Carcinoma. 2017;4:93\u2013103.","journal-title":"J Hepatocell Carcinoma"},{"issue":"3","key":"1911_CR5","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.jhep.2014.05.016","volume":"61","author":"T Boettler","year":"2014","unstructured":"Boettler T, et al. Bridging basic science and clinical research: the EASL monothematic conference on translational research in viral hepatitis. J Hepatol. 2014;61(3):696\u2013705.","journal-title":"J Hepatol"},{"issue":"1","key":"1911_CR6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/SLA.0b013e3182363ff9","volume":"255","author":"LT Chen","year":"2012","unstructured":"Chen LT, et al. Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection. Ann Surg. 2012;255(1):8\u201317.","journal-title":"Ann Surg"},{"issue":"7","key":"1911_CR7","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1158\/2159-8290.CD-21-1022","volume":"12","author":"B Hu","year":"2022","unstructured":"Hu B, et al. IFN\u03b1 potentiates Anti-PD-1 efficacy by remodeling glucose metabolism in the hepatocellular carcinoma microenvironment. Cancer Discov. 2022;12(7):1718\u201341.","journal-title":"Cancer Discov"},{"issue":"3","key":"1911_CR8","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10147-010-0151-9","volume":"16","author":"K Kasai","year":"2011","unstructured":"Kasai K, et al. Combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon \u03b1-2b for advanced hepatocellular carcinoma. Int J Clin Oncol. 2011;16(3):221\u20139.","journal-title":"Int J Clin Oncol"},{"issue":"6","key":"1911_CR9","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s11096-015-0177-1","volume":"37","author":"M Masip","year":"2015","unstructured":"Masip M, et al. Prevalence and detection of neuropsychiatric adverse effects during hepatitis C treatment. Int J Clin Pharm. 2015;37(6):1143\u201351.","journal-title":"Int J Clin Pharm"},{"key":"1911_CR10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/978-94-017-7555-7_2","volume":"909","author":"R Liu","year":"2016","unstructured":"Liu R, et al. Biological response modifier in Cancer immunotherapy. Adv Exp Med Biol. 2016;909:69\u2013138.","journal-title":"Adv Exp Med Biol"},{"key":"1911_CR11","doi-asserted-by":"publisher","first-page":"865973","DOI":"10.3389\/fimmu.2022.865973","volume":"13","author":"K Nakagome","year":"2022","unstructured":"Nakagome K, Nagata M. Innate immune responses by respiratory viruses, including rhinovirus, during asthma exacerbation. Front Immunol. 2022;13:865973.","journal-title":"Front Immunol"},{"issue":"11","key":"1911_CR12","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1159\/000524097","volume":"106","author":"E Bonetti","year":"2022","unstructured":"Bonetti E, et al. Interleukin-2 and Interferon-\u03b1 for advanced renal cell carcinoma: patient outcomes, sexual dimorphism of responses, and multimodal treatment approaches over a 30-Year period. Urol Int. 2022;106(11):1158\u201367.","journal-title":"Urol Int"},{"key":"1911_CR13","doi-asserted-by":"crossref","unstructured":"Nishida T, Kataoka H. Glypican 3-Targeted therapy in hepatocellular carcinoma. Cancers (Basel), 2019. 11(9).","DOI":"10.3390\/cancers11091339"},{"issue":"10","key":"1911_CR14","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1097\/PAI.0000000000001080","volume":"30","author":"AS Mohamed","year":"2022","unstructured":"Mohamed AS, et al. Diagnostic and prognostic value of isolated and combined MCM3 and Glypican-3 expression in hepatocellular carcinoma: A novel immunosubtyping prognostic model. Appl Immunohistochem Mol Morphol. 2022;30(10):694\u2013702.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"6","key":"1911_CR15","first-page":"1067","volume":"4","author":"D Yang","year":"2011","unstructured":"Yang D, et al. A new membrane re-anchored protein originating from GPC3 against hepatoma cells HepG2. Mol Med Rep. 2011;4(6):1067\u201373.","journal-title":"Mol Med Rep"},{"issue":"1","key":"1911_CR16","doi-asserted-by":"publisher","first-page":"2381891","DOI":"10.1080\/19420862.2024.2381891","volume":"16","author":"P Murer","year":"2024","unstructured":"Murer P, et al. Discovery and development of ANV419, an IL-2\/anti-IL-2 antibody fusion protein with potent CD8\u2009+\u2009T and natural killer cell-stimulating capacity for cancer immunotherapy. MAbs. 2024;16(1):2381891.","journal-title":"MAbs"},{"issue":"9","key":"1911_CR17","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1038\/s43018-023-00612-0","volume":"4","author":"W Wu","year":"2023","unstructured":"Wu W, et al. IL-2R\u03b1-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25(+)CD8(+) T cells. Nat Cancer. 2023;4(9):1309\u201325.","journal-title":"Nat Cancer"},{"key":"1911_CR18","doi-asserted-by":"crossref","unstructured":"Mathiot L et al. Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed\/refractory advanced solid tumors. J Immunother Cancer, 2024. 12(5).","DOI":"10.1136\/jitc-2024-008847"},{"issue":"5","key":"1911_CR19","doi-asserted-by":"publisher","first-page":"101531","DOI":"10.1016\/j.xcrm.2024.101531","volume":"5","author":"W Shi","year":"2024","unstructured":"Shi W, et al. Next-generation anti-PD-L1\/IL-15 Immunocytokine elicits superior antitumor immunity in cold tumors with minimal toxicity. Cell Rep Med. 2024;5(5):101531.","journal-title":"Cell Rep Med"},{"key":"1911_CR20","doi-asserted-by":"publisher","first-page":"122279","DOI":"10.1016\/j.biomaterials.2023.122279","volume":"301","author":"Y Yan","year":"2023","unstructured":"Yan Y, et al. Branched hydrophobic Tails in lipid nanoparticles enhance mRNA delivery for cancer immunotherapy. Biomaterials. 2023;301:122279.","journal-title":"Biomaterials"},{"key":"1911_CR21","doi-asserted-by":"crossref","unstructured":"Wadhwa A et al. Opportunities and challenges in the delivery of mRNA-based vaccines. Pharmaceutics, 2020. 12(2).","DOI":"10.3390\/pharmaceutics12020102"},{"key":"1911_CR22","doi-asserted-by":"crossref","unstructured":"Rivero Berti I et al. Encapsulation of dexamethasone into mRNA-Lipid nanoparticles is a promising approach for the development of Liver-Targeted Anti-Inflammatory therapies. Int J Mol Sci, 2024. 25(20).","DOI":"10.3390\/ijms252011254"},{"key":"1911_CR23","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jconrel.2024.10.035","volume":"376","author":"SM Eslami","year":"2024","unstructured":"Eslami SM, Lu X. Recent advances in mRNA-based cancer vaccines encoding immunostimulants and their delivery strategies. J Control Release. 2024;376:413\u201328.","journal-title":"J Control Release"},{"issue":"4","key":"1911_CR24","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi N, et al. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261\u201379.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"1911_CR25","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.tcb.2016.11.007","volume":"27","author":"C Rabouille","year":"2017","unstructured":"Rabouille C. Pathways of unconventional protein secretion. Trends Cell Biol. 2017;27(3):230\u201340.","journal-title":"Trends Cell Biol"},{"issue":"3","key":"1911_CR26","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1194\/jlr.R062760","volume":"57","author":"M Mu\u00f1\u00edz","year":"2016","unstructured":"Mu\u00f1\u00edz M, Riezman H. Trafficking of glycosylphosphatidylinositol anchored proteins from the Endoplasmic reticulum to the cell surface. J Lipid Res. 2016;57(3):352\u201360.","journal-title":"J Lipid Res"},{"key":"1911_CR27","doi-asserted-by":"publisher","first-page":"716844","DOI":"10.3389\/fonc.2021.716844","volume":"11","author":"Y He","year":"2021","unstructured":"He Y, et al. Biomarkers and future perspectives for hepatocellular carcinoma immunotherapy. Front Oncol. 2021;11:716844.","journal-title":"Front Oncol"},{"issue":"6","key":"1911_CR28","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.3748\/wjg.v29.i6.1054","volume":"29","author":"DS Mandlik","year":"2023","unstructured":"Mandlik DS, Mandlik SK, Choudhary HB. Immunotherapy for hepatocellular carcinoma: current status and future perspectives. World J Gastroenterol. 2023;29(6):1054\u201375.","journal-title":"World J Gastroenterol"},{"issue":"7","key":"1911_CR29","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1111\/jgh.15889","volume":"37","author":"SL Chan","year":"2022","unstructured":"Chan SL, et al. Personalized treatment for hepatocellular carcinoma: current status and future perspectives. J Gastroenterol Hepatol. 2022;37(7):1197\u2013206.","journal-title":"J Gastroenterol Hepatol"},{"issue":"43","key":"1911_CR30","doi-asserted-by":"publisher","first-page":"69916","DOI":"10.18632\/oncotarget.12066","volume":"7","author":"AO Kaseb","year":"2016","unstructured":"Kaseb AO, et al. Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma. Oncotarget. 2016;7(43):69916\u201326.","journal-title":"Oncotarget"},{"key":"1911_CR31","doi-asserted-by":"crossref","unstructured":"Guan L et al. GPC3-targeted CAR-M cells exhibit potent antitumor activity against hepatocellular carcinoma. Biochem Biophys Rep, 2024. 39.","DOI":"10.1016\/j.bbrep.2024.101741"},{"key":"1911_CR32","doi-asserted-by":"crossref","unstructured":"Gan Q, Shao J, Sun TL. The inhibitory effects of Anti-GPC3 antibody on Wnt\/\u03b2-Catenin signaling pathway as a biological therapy in liver Cancer. Molecular Biotechnology; 2024.","DOI":"10.1007\/s12033-024-01291-7"},{"key":"1911_CR33","doi-asserted-by":"crossref","unstructured":"Tojjari A et al. Exploring Glypican-3 as a molecular target in hepatocellular carcinoma: perspectives on diagnosis and precision immunotherapy strategies. Front Bioscience-Landmark, 2024. 29(7).","DOI":"10.31083\/j.fbl2907268"},{"issue":"10","key":"1911_CR34","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1080\/14728222.2024.2416975","volume":"28","author":"A Couzinet","year":"2024","unstructured":"Couzinet A, Suzuki T, Nakatsura T. Progress and challenges in glypican-3 targeting for hepatocellular carcinoma therapy. Expert Opin Ther Targets. 2024;28(10):895\u2013909.","journal-title":"Expert Opin Ther Targets"},{"issue":"1","key":"1911_CR35","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.drudis.2015.10.012","volume":"21","author":"F Bootz","year":"2016","unstructured":"Bootz F, Neri D. Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions. Drug Discov Today. 2016;21(1):180\u20139.","journal-title":"Drug Discov Today"},{"issue":"1","key":"1911_CR36","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1038\/s41467-023-38751-8","volume":"14","author":"W Tai","year":"2023","unstructured":"Tai W, et al. An mRNA-based T-cell-inducing antigen strengthens COVID-19 vaccine against SARS-CoV-2 variants. Nat Commun. 2023;14(1):2962.","journal-title":"Nat Commun"},{"issue":"3","key":"1911_CR37","first-page":"e2022236","volume":"93","author":"A Nashwan","year":"2022","unstructured":"Nashwan A, et al. mRNA-based COVID-19 vaccines booster dose: benefits, risks and coverage. Acta Biomed. 2022;93(3):e2022236.","journal-title":"Acta Biomed"},{"issue":"51","key":"1911_CR38","doi-asserted-by":"publisher","first-page":"e2303261","DOI":"10.1002\/adma.202303261","volume":"35","author":"Y Zong","year":"2023","unstructured":"Zong Y, et al. Lipid nanoparticle (LNP) enables mRNA delivery for Cancer therapy. Adv Mater. 2023;35(51):e2303261.","journal-title":"Adv Mater"},{"key":"1911_CR39","doi-asserted-by":"publisher","first-page":"589959","DOI":"10.3389\/fchem.2020.589959","volume":"8","author":"ML Guevara","year":"2020","unstructured":"Guevara ML, Persano F, Persano S. Advances in lipid nanoparticles for mRNA-Based Cancer immunotherapy. Front Chem. 2020;8:589959.","journal-title":"Front Chem"},{"issue":"6","key":"1911_CR40","doi-asserted-by":"publisher","first-page":"6412","DOI":"10.1021\/acsnano.4c16562","volume":"19","author":"W Park","year":"2025","unstructured":"Park W, et al. Apolipoprotein fusion enables spontaneous functionalization of mRNA lipid nanoparticles with antibody for targeted Cancer therapy. ACS Nano. 2025;19(6):6412\u201325.","journal-title":"ACS Nano"},{"issue":"1","key":"1911_CR41","doi-asserted-by":"publisher","first-page":"2255041","DOI":"10.1080\/2162402X.2023.2255041","volume":"12","author":"H B\u00e4hr-Mahmud","year":"2023","unstructured":"B\u00e4hr-Mahmud H, et al. Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody. Oncoimmunology. 2023;12(1):2255041.","journal-title":"Oncoimmunology"},{"key":"1911_CR42","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.omtn.2023.06.023","volume":"33","author":"K Yamazaki","year":"2023","unstructured":"Yamazaki K, et al. Lipid nanoparticle-targeted mRNA formulation as a treatment for ornithine-transcarbamylase deficiency model mice. Mol Ther Nucleic Acids. 2023;33:210\u201326.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"6","key":"1911_CR43","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/s41423-022-00848-3","volume":"19","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, et al. The combination of PD-1 Blockade with interferon-\u03b1 has a synergistic effect on hepatocellular carcinoma. Cell Mol Immunol. 2022;19(6):726\u201337.","journal-title":"Cell Mol Immunol"},{"key":"1911_CR44","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.jconrel.2023.04.005","volume":"357","author":"SG Huayamares","year":"2023","unstructured":"Huayamares SG, et al. High-throughput screens identify a lipid nanoparticle that preferentially delivers mRNA to human tumors in vivo. J Controlled Release. 2023;357:394\u2013403.","journal-title":"J Controlled Release"},{"key":"1911_CR45","doi-asserted-by":"crossref","unstructured":"Su KX et al. Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation. Nat Commun, 2024. 15(1).","DOI":"10.1038\/s41467-024-50093-7"},{"key":"1911_CR46","doi-asserted-by":"crossref","unstructured":"Cho K et al. Genetically engineered mouse models for liver Cancer. Cancers, 2020. 12(1).","DOI":"10.3390\/cancers12010014"},{"issue":"5","key":"1911_CR47","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1002\/hep.32707","volume":"77","author":"DJ Zabransky","year":"2023","unstructured":"Zabransky DJ, et al. Profiling of syngeneic mouse HCC tumor models as a framework to understand anti-PD-1 sensitive tumor microenvironments. Hepatology. 2023;77(5):1566\u201379.","journal-title":"Hepatology"},{"issue":"3","key":"1911_CR48","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.gendis.2020.03.010","volume":"7","author":"XD Zhu","year":"2020","unstructured":"Zhu XD, Tang ZY, Sun HC. Targeting angiogenesis for liver cancer: past, present, and future. Genes Dis. 2020;7(3):328\u201335.","journal-title":"Genes Dis"},{"key":"1911_CR49","doi-asserted-by":"crossref","unstructured":"Zhu HZ et al. Evaluation of the effectiveness and safety of combining PD-1\/PD-L1 inhibitors with anti-angiogenic agents in unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Front Immunol, 2024. 15.","DOI":"10.3389\/fimmu.2024.1468440"},{"key":"1911_CR50","doi-asserted-by":"crossref","unstructured":"Crimini E et al. Beyond PD(L)-1 Blockade in Microsatellite-Instable cancers: current landscape of immune Co-Inhibitory receptor targeting. Cancers, 2024. 16(2).","DOI":"10.3390\/cancers16020281"},{"key":"1911_CR51","doi-asserted-by":"crossref","unstructured":"Ho TTB et al. Combination of gemcitabine and anti-PD-1 antibody enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer liver metastasis. J Immunother Cancer, 2020. 8(2).","DOI":"10.1136\/jitc-2020-001367"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-025-01911-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-025-01911-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-025-01911-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T14:41:18Z","timestamp":1768920078000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-025-01911-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1911"],"URL":"https:\/\/doi.org\/10.1007\/s13346-025-01911-y","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,4]]},"assertion":[{"value":"24 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experimental procedures involving animals have been approved by the Animal Ethics Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}